+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
JUBLPHARMA

Jubilant Pharmova Share Price

₹1,048.20 -12.25 (-1.16%)
33.35% Gain from 52W Low

29 Sep, 2026 3:54 PM (IST)

Jubilant Pharmova live price: ₹1,048.20. It opened at ₹1,058 vs previous close ₹1,060; intraday high/low: ₹1,090/₹1,036. The 50 & 200 DMA stand at ₹979.20/₹973.60.

Jubilant Pharmova Performance

  • Today's Low
  • ₹1,036
  • Today's High
  • ₹1,090
  • 52 Week Low
  • ₹786
  • 52 Week High
  • ₹1,185
  • Open Price₹1,058
  • Previous Close₹1,060
  • Volume1,078,699
  • 50 DMA₹979.20
  • 100 DMA₹967.50
  • 200 DMA₹973.60

Jubilant Pharmova Chart

Investment Returns

  • Over 1 Month + 18.76%
  • Over 3 Month + 8.69%
  • Over 6 Month + 24.16%
  • Over 1 Year + 0.51%

Smart Investing Starts Here Start SIP with Jubilant Pharmova for Steady Growth!

Invest Now

Jubilant Pharmova Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 47.4
  • PEG Ratio
  • -2
  • Market Cap Cr
  • 16,696
  • P/B Ratio
  • 2.3
  • Average True Range
  • 36
  • EPS
  • 22.1
  • Dividend Yield
  • 0.5
  • MACD Signal
  • 35.9
  • RSI
  • 62.43
  • MFI
  • 55.66

Latest Stock News Updates

Jubilant Pharmova Ltd - 530019 - Closure of Trading Window

Intimation regarding Closure of Trading Window for the Quarter ended September 30, 2026

Jubilant Pharmova Ltd - 530019 - Specimen Letter Sent To Shareholders For Withheld Of Dividend For FY 2025-26

Specimen letter sent to shareholders for withheld of dividend for FY 2025-26

Jubilant Pharmova's Spokane facility receives VAI classification from US FDA

The classification follows a June inspection, with the regulator indicating that the identified conditions do not warrant administrative or regulatory action.

Jubilant Pharmova Financials

Jubilant Pharmova Technicals

EMA & SMA

Current Price
₹1,048.20
-12.25 (-1.16%)
pointer
  • Bearish Moving Average 3
  • Bullish Moving Average 13
  • 20 Day
  • ₹1,016.00
  • 50 Day
  • ₹979.20
  • 100 Day
  • ₹967.50
  • 200 Day
  • ₹973.60

Resistance and Support

1058 Pivot Speed
  • R3 1,133.30
  • R2 1,111.50
  • R1 1,079.80
  • S1 1,026.40
  • S2 1,004.60
  • S3 972.90

Jubilant Pharmova Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-08-10 Quarterly Results (Revised)
2026-05-22 Audited Results & Final Dividend
2026-02-06 Quarterly Results
2025-10-31 Quarterly Results
2025-07-29 Quarterly Results
Date Purpose Remarks
2026-07-24 FINAL Rs.5.00 per share(500%)Final Dividend
2025-07-25 FINAL Rs.5.00 per share(500%)Final Dividend
2024-08-02 FINAL Rs.5.00 per share(500%)Final Dividend
2023-08-10 FINAL Rs.5.00 per share(500%)Final Dividend
2022-08-12 FINAL Rs.5.00 per share(500%)Final Dividend
View Jubilant Pharmova Dividend History Arrow
Date Purpose Remarks
2006-03-24 Split Stock split from Rs. 5/- to Re. 1/-
2002-11-21 Split Face value changed from Rs. 10/- to Rs. 5/-

Jubilant Pharmova Shareholding Pattern

47.68%
23.5%
15.87%
8.99%
3.41%

About Jubilant Pharmova

Jubilant Pharmova engaged in six businesses, including Radiopharma, Allergy Immunotherapy, Contract Development and Manufacturing of sterile injectables, Contract Research Development and Manufacturing, Generics and Proprietary Novel Drugs businesses. View More
  • NSE Symbol
  • JUBLPHARMA
  • BSE Symbol
  • 530019
  • ISIN
  • INE700A01033

Similar Stocks to Jubilant Pharmova

Jubilant Pharmova FAQs

Jubilant Pharmova share price is ₹1,048 As on 29 September, 2026 | 18:41

The Market Cap of Jubilant Pharmova is ₹16695.8 Cr As on 29 September, 2026 | 18:41

The P/E ratio of Jubilant Pharmova is 47.4 As on 29 September, 2026 | 18:41

The PB ratio of Jubilant Pharmova is 2.3 As on 29 September, 2026 | 18:41

The 52 week High & Low of Jubilant Pharmova is ₹1184.8/₹786 respectively As on 29 September, 2026 | 18:41

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23